Trial Profile

A clinical study of of CTA313 in patients with SLE/LN.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTA 313 (Primary) ; Cyclophosphamide; Fludarabine
Indications Lupus nephritis; Systemic lupus erythematosus
Focus Adverse reactions

Most Recent Events

02 Mar 2026 According to Imviva Biotech media release, the company announced that its abstract detailing clinical results ongoing Phase 1/2 trial in systemic lupus erythematosus (SLE) for CTA313, a CD19/BCMA dual-targeted allogeneic CAR-T cell therapy, has been accepted as a late-breaking short oral presentation at the 15th European Lupus Meeting (ELM 2026). The presentation will be featured in the Late Breaking session on March 6, 2026, taking place March 4-7 in Lisbon, Portugal.
04 Dec 2025 New trial record
30 Oct 2025 According to Imviva Biotech media release, data from this study were presented at ACR.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com